TrialDiabetes, obesity & metabolism2022

Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.

Melanie J Davies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.